OBJECTIVE: The objective of the present study was to evaluate the pharmacokinetics and the clearance pathways of rFVIIa after intravenous administration to hemophilia patients. METHODS: Ten severe hemophilia patients were included in the study; all patients were intravenously administered a clinically relevant dose of 90 μg kg(-1) (1.8 nmol kg(-1)) rFVIIa. Blood samples were collected consecutively to describe the pharmacokinetics of rFVIIa. All samples were analyzed using three different assays: a clot assay to measure the activity (FVIIa:C), an enzyme immunoassay (EIA) to measure the antigen levels (FVII:Ag), and an EIA (FVIIa-AT) to measure the FVIIa antithrombin III (AT) complex. Pharmacokinetic parameters were evaluated both by use of standard non-compartmental methods and by use of mixed effects methods. A population pharmacokinetic model was used to simultaneously model all three datasets. The total body clearance of rFVIIa:C was estimated to be 38 mL h(-1) kg(-1). The rFVII-AT complex formation was responsible for 65% of the total rFVIIa:C clearance. The initial and the terminal half-life of rFVIIa:C was estimated to be 0.6 and 2.6 h, respectively. The formation of rFVII-AT complex was able to explain the difference observed between the rFVIIa:C and the rFVII:Ag concentration. The non-compartmental analysis resulted in almost identical parameters.
OBJECTIVE: The objective of the present study was to evaluate the pharmacokinetics and the clearance pathways of rFVIIa after intravenous administration to hemophiliapatients. METHODS: Ten severe hemophiliapatients were included in the study; all patients were intravenously administered a clinically relevant dose of 90 μg kg(-1) (1.8 nmol kg(-1)) rFVIIa. Blood samples were collected consecutively to describe the pharmacokinetics of rFVIIa. All samples were analyzed using three different assays: a clot assay to measure the activity (FVIIa:C), an enzyme immunoassay (EIA) to measure the antigen levels (FVII:Ag), and an EIA (FVIIa-AT) to measure the FVIIa antithrombin III (AT) complex. Pharmacokinetic parameters were evaluated both by use of standard non-compartmental methods and by use of mixed effects methods. A population pharmacokinetic model was used to simultaneously model all three datasets. The total body clearance of rFVIIa:C was estimated to be 38 mL h(-1) kg(-1). The rFVII-AT complex formation was responsible for 65% of the total rFVIIa:C clearance. The initial and the terminal half-life of rFVIIa:C was estimated to be 0.6 and 2.6 h, respectively. The formation of rFVII-AT complex was able to explain the difference observed between the rFVIIa:C and the rFVII:Ag concentration. The non-compartmental analysis resulted in almost identical parameters.
Authors: C M Lindley; W T Sawyer; B G Macik; J Lusher; J F Harrison; K Baird-Cox; K Birch; S Glazer; H R Roberts Journal: Clin Pharmacol Ther Date: 1994-06 Impact factor: 6.875
Authors: Lars C Petersen; Ditte M Karpf; Henrik Agersø; Mette B Hermit; Hermann Pelzer; Egon Persson; Timothy C Nichols; Mirella Ezban Journal: Br J Haematol Date: 2010-11-18 Impact factor: 6.998
Authors: Mareike K Körber; Elisabeth Langer; Lutz Kaufner; Michael Sander; Christian Von Heymann Journal: Blood Transfus Date: 2016-04-28 Impact factor: 3.443
Authors: Derek S Sim; Cornell R Mallari; John M Teare; Richard I Feldman; Maxine Bauzon; Terry W Hermiston Journal: Res Pract Thromb Haemost Date: 2021-06-30
Authors: Ernst Böhm; Birgit K Seyfried; Michael Dockal; Michael Graninger; Meinhard Hasslacher; Marianne Neurath; Christian Konetschny; Peter Matthiessen; Artur Mitterer; Friedrich Scheiflinger Journal: BMC Biotechnol Date: 2015-09-18 Impact factor: 2.563
Authors: S Zollner; D Schuermann; E Raquet; J Mueller-Cohrs; T Weimer; I Pragst; G Dickneite; S Schulte Journal: J Thromb Haemost Date: 2014-02 Impact factor: 5.824
Authors: Anders L Nielsen; Anders B Sorensen; Heidi L Holmberg; Prafull S Gandhi; Johan Karlsson; Jens Buchardt; Kasper Lamberth; Mads Kjelgaard-Hansen; Carsten Dan Ley; Brit B Sørensen; Wolfram Ruf; Ole H Olsen; Henrik Østergaard Journal: Proc Natl Acad Sci U S A Date: 2017-11-06 Impact factor: 11.205